Amanote Research
Register
Sign In
Orphan Designation: Humanised Anti-Il-6 Receptor Monoclonal Antibody, Treatment of Neuromyelitis Optica Spectrum Disorders
Case Medical Research
doi 10.31525/cmr-977fca
Full Text
Open PDF
Abstract
Available in
full text
Date
September 19, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Orphan Designation: Recombinant Human Anti-Interferon Gamma Monoclonal Antibody (Emapalumab), Treatment of Haemophagocytic Lymphohistiocytosis
Case Medical Research
Monoclonal Antibody Treatment During Pregnancy and/or Lactation in Women With MS or Neuromyelitis Optica Spectrum Disorder
Neurology: Neuroimmunology and NeuroInflammation
Neurology
Neuromyelitis Optica Spectrum Disorders: A Definite Case With Autoimmune Thyroiditis
International Journal of Clinical Neurosciences and Mental Health
Increased Serum IL-36β and IL-36γ Levels in Patients With Neuromyelitis Optica Spectrum Disorders: Association With Disease Activity
BMC Neurology
Medicine
Neurology
Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-Cd20 Therapy
JAMA Neurology
Neurology
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
Current Treatment Options in Neurology
Neurology
The Neuromyelitis Optica Spectrum Disorders: Approaches for Problem Resolution in Medical Rehabilitation
The Scientific Notes of the I. P. Pavlov St. Petersburg State Medical University
Elevated Plasma Chemokines for Eosinophils in Neuromyelitis Optica Spectrum Disorders During Remission
Frontiers in Neurology
Neurology
Tumefactive Demyelination Associated With Bilateral Optic Neuritis in Neuromyelitis Optica Spectrum Disorders
Journal of Neurosciences in Rural Practice
Neuroscience
Neurology
